Pfizer reported a total of $36.78 billion in global direct sales and alliance revenue from its two-dose COVID-19 vaccine in 2021 and intends to top that incredible amount of revenue this year.
In an earnings report released Tuesday, the company said it expects to reach $54 billion in sales in 2022 with two projects aimed at the health crisis: $32 billion in gross revenue for the vaccine and $22 billion in gross revenue for its COVID-19 antiviral treatment, Paxlovid.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.